In summary, we identified for the first time three novel miRNAs (miR-1244, miR-193b-5p, and miR-1231) with prognostic value on EFS and OS in patients with DLBCL, and confirmed in vitro that the downregulation of the first two inhibits cell viability and increases resistance to CHOP treatment in DLBCL cells. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.